Hydroxyurea and Gut Microbiome Interactions in Sickle Cell Disease: Toward Adjunctive Microbiome-based Therapy

Area of Science:

• Hematology
• Microbiology
• Immunology

Background:

• Sickle cell disease (SCD) is a complex inflammatory disorder causing significant morbidity despite current treatments.
• Hydroxyurea is a primary treatment for SCD, inducing fetal hemoglobin and reducing complications, but it has limitations in addressing persistent inflammation and organ damage.
• The gut microbiome plays a crucial role in immune homeostasis and inflammation, and its dysregulation is implicated in SCD pathogenesis.

Purpose of the Study:

• To review the interplay between hydroxyurea and the gut microbiome in SCD.
• To explore the potential of microbiome-directed therapies as adjuncts to conventional SCD treatment.
• To evaluate how these combined strategies can mitigate inflammation and organ damage in SCD patients.

Main Methods:

• Literature review synthesizing current evidence on hydroxyurea, gut microbiome, and SCD.
• Analysis of studies investigating dysbiosis in SCD and its impact on inflammation and organ damage.
• Evaluation of emerging microbiome-directed therapies, including probiotics and microbial metabolites.

Main Results:

• SCD is characterized by gut dysbiosis, reduced microbial diversity, and diminished short-chain fatty acid (SCFA) production, contributing to inflammation and endothelial dysfunction.
• Hydroxyurea may partially restore gut microbial balance, but residual dysbiosis persists, indicating a need for complementary therapies.
• Microbiome-directed therapies show promise in reducing pro-inflammatory cytokines, enhancing gut barrier function, and modulating immune responses.

Conclusions:

• A combined approach using hydroxyurea and microbiome-based interventions may offer superior control of inflammation and organ damage in SCD.
• Probiotics and SCFA-mediated pathways present potential adjunctive strategies to address therapeutic gaps left by hydroxyurea.
• Integrating microbiome interventions with conventional SCD therapy offers a promising patient-centered approach to improve long-term outcomes and quality of life.